Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting

NCT00622843 · View on ClinicalTrials.gov ↗

Study Summary

Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.

Interventions

  • BIOLOGICAL pneumococcal conjugate vaccine
  • BIOLOGICAL pneumococcal polysaccharide vaccine

Study Locations (6)

California

  • Naval Medical Center San Diego — San Diego

District of Columbia

  • Walter Reed Army Medical Center — Washington D.C.

Hawaii

  • Tripler Army Medical Center — Tripler AMC

Maryland

  • National Naval Medical Center — Bethesda

Texas

  • San Antonio Military Medical Center — Lackland Air Force Base

Virginia

  • Naval Medical Center Portsmouth — Portsmouth

Trial Details

FieldValue
Enrollment Target 275 participants
Start Date 2002-12
Est. Completion 2013-07
Phase Phase 3

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00622843

The ClinicalTrials.gov registry entry for NCT00622843 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 79 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions — of which pneumococcal conjugate vaccine is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00622843 reports 6 study locations spanning 6 distinct geographic areas — top geographies include California, District of Columbia, Hawaii. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00622843 about?

NCT00622843 is a clinical study titled "Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting". Purpose: To study the immune response of the newly licensed pneumococcal conjugate vaccine (PCV) in comparison to the pneumococcal polysaccharide vaccine (PPV) to determine if a significantly better immunologic response to boosting can be elicited in patients previously vaccinated with PPV.

What is the current status of trial NCT00622843?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 275 participants. The study started on 2002-12. Estimated completion is 2013-07.

What conditions does trial NCT00622843 study?

This clinical trial studies the following conditions: HIV Infections, Streptococcus Pneumoniae. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00622843?

The interventions under investigation include: pneumococcal conjugate vaccine (BIOLOGICAL), pneumococcal polysaccharide vaccine (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00622843?

This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 79 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00622843 being conducted?

This trial has 6 study locations across California, District of Columbia, Hawaii, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial